Alexandra Drakaki

Title(s)HS Associate Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)HS Associate Clinical Professor, Urology


    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024 Mar 07; 390(10):875-888. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüs M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS, EV-302 Trial Investigators. PMID: 38446675.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma. Cancer Invest. 2024 Jan; 42(1):97-103. Lebacle C, Pooli A, Shuch B, Rao N, Chamie K, Kroeger N, Faiena I, Liu S, Wood EL, Belldegrun A, Drakaki A, Pantuck AJ. PMID: 38314786.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst. 2023 12 06; 115(12):1605-1615. El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. PMID: 37563779.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    4. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023 11 01; 29(21):4373-4384. Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Fléchon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. PMID: 37651261.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    5. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830. Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG. PMID: 38027216; PMCID: PMC10643762.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023 Oct 30; 13(1):95. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. PMID: 37902861; PMCID: PMC10616012.
      View in: PubMed   Mentions:
    7. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023 Oct 02; 7(1):18. Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J, Sonni I. PMID: 37779132; PMCID: PMC10542625.
      View in: PubMed   Mentions:
    8. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023 11; 64(11):1737-1743. Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. PMID: 37678927.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma. Curr Oncol. 2023 08 04; 30(8):7398-7411. Hui G, Stefanoudakis D, Zektser Y, Isaacs DJ, Hannigan C, Pantuck AJ, Drakaki A. PMID: 37623017; PMCID: PMC10452970.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. Clin Genitourin Cancer. 2023 10; 21(5):584-593. Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, Agarwal N, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Korolewicz J, Jindal T, Koshkin VS, Murgic J, Miletic M, Frobe A, Johnson J, Zakharia Y, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Carballeira CC, Barrera RM, Marmorejo D, McKay RR, Stewart T, Gupta S, Ruplin AT, Yu EY, Khaki AR, Grivas P. PMID: 37414620.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Clonally expanded, thyrotoxic effector CD8+ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. Sci Transl Med. 2023 05 17; 15(696):eadg0675. Lechner MG, Zhou Z, Hoang AT, Huang N, Ortega J, Scott LN, Chen HC, Patel AY, Yakhshi-Tafti R, Kim K, Hugo W, Famini P, Drakaki A, Ribas A, Angell TE, Su MA. PMID: 37196065; PMCID: PMC10227862.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    12. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023 07 20; 41(21):3712-3723. El Zarif T, Nassar AH, Adib E, Fitzgerald BG, Huang J, Mouhieddine TH, Rubinstein PG, Nonato T, McKay RR, Li M, Mittra A, Owen DH, Baiocchi RA, Lorentsen M, Dittus C, Dizman N, Falohun A, Abdel-Wahab N, Diab A, Bankapur A, Reed A, Kim C, Arora A, Shah NJ, El-Am E, Kozaily E, Abdallah W, Al-Hader A, Abu Ghazal B, Saeed A, Drolen C, Lechner MG, Drakaki A, Baena J, Nebhan CA, Haykal T, Morse MA, Cortellini A, Pinato DJ, Dalla Pria A, Hall E, Bakalov V, Bahary N, Rajkumar A, Mangla A, Shah V, Singh P, Aboubakar Nana F, Lopetegui-Lia N, Dima D, Dobbs RW, Funchain P, Saleem R, Woodford R, Long GV, Menzies AM, Genova C, Barletta G, Puri S, Florou V, Idossa D, Saponara M, Queirolo P, Lamberti G, Addeo A, Bersanelli M, Freeman D, Xie W, Reid EG, Chiao EY, Sharon E, Johnson DB, Ramaswami R, Bower M, Emu B, Marron TU, Choueiri TK, Baden LR, Lurain K, Sonpavde GP, Naqash AR. PMID: 37192435; PMCID: PMC10351941.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    13. The Potential Revolution of Cancer Treatment with CRISPR Technology. Cancers (Basel). 2023 Mar 17; 15(6). Stefanoudakis D, Kathuria-Prakash N, Sun AW, Abel M, Drolen CE, Ashbaugh C, Zhang S, Hui G, Tabatabaei YA, Zektser Y, Lopez LP, Pantuck A, Drakaki A. PMID: 36980699; PMCID: PMC10046289.
      View in: PubMed   Mentions: 4  
    14. Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2023 04; 21(2):286-294. Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, Agarwal N, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi CM, Cortellini A, Pinato D, Barata P, Grivas P, Khaki AR, Koshkin VS. PMID: 36481176.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 12; 20(6):558-567. Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. PMID: 36155169; PMCID: PMC10233855.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. J Immunol. 2022 08 15; 209(4):696-709. Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA. PMID: 35817515; PMCID: PMC9378719.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    17. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 10; 20(5):e440-e452. Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Jang A, Barata P, Sonpavde G, Yu EY, Montgomery RB, Grivas P, Khaki AR. PMID: 35778337; PMCID: PMC10257151.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    18. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. Eur J Cancer. 2022 06; 168:68-76. Kroeger N, Lebacle C, Hein J, Rao PN, Nejati R, Wei S, Burchardt M, Drakaki A, Strother M, Kutikov A, Uzzo R, Pantuck AJ. PMID: 35461012.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nat Commun. 2022 04 06; 13(1):1878. van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA, Bamias A, Gakis G, Lee JL, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Eigl BJ, Hozak RR, Rasmussen ER, Xia MS, Rhodes R, Wijayawardana S, Bell-McGuinn KM, Aggarwal A, Drakaki A. PMID: 35388003; PMCID: PMC8987042.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis. Thyroid. 2022 05; 32(5):496-504. Mosaferi T, Tsai K, Sovich S, Wilhalme H, Kathuria-Prakash N, Praw SS, Drakaki A, Angell TE, Lechner MG. PMID: 35199588; PMCID: PMC9145255.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    21. Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. Life (Basel). 2022 Mar 02; 12(3). Hui G, Drolen C, Hannigan CA, Drakaki A. PMID: 35330111; PMCID: PMC8949122.
      View in: PubMed   Mentions:
    22. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. Br J Clin Pharmacol. 2022 07; 88(7):3182-3192. de Wit R, Powles T, Castellano D, Necchi A, Lee JL, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN, Drakaki A, Yu EY, Zimmermann AH, Long A, Walgren RA, Gao L, Bell-McGuinn KM, Petrylak DP. PMID: 35029306; PMCID: PMC9302693.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    23. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. J Immunother Cancer. 2022 02; 10(2). Weidhaas J, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, Carrillo J, Drakaki A, Scholz M, Telesca D. PMID: 35115362; PMCID: PMC8804679.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches. Life (Basel). 2021 Dec 24; 12(1). Kathuria-Prakash N, Drolen C, Hannigan CA, Drakaki A. PMID: 35054417; PMCID: PMC8781308.
      View in: PubMed   Mentions: 11  
    25. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clin Genitourin Cancer. 2022 04; 20(2):165-175. Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. PMID: 35078711; PMCID: PMC8995351.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 2022 03 01; 128(5):966-974. Emamekhoo H, Olsen MR, Carthon BC, Drakaki A, Percent IJ, Molina AM, Cho DC, Bendell JC, Gordan LN, Rezazadeh Kalebasty A, George DJ, Hutson TE, Arrowsmith ER, Zhang J, Zoco J, Johansen JL, Leung DK, Tykodi SS. PMID: 34784056; PMCID: PMC9298991.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    27. Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. Clin Genitourin Cancer. 2022 04; 20(2):e94-e103. Xiang M, Chang AJ, Chamie K, Drakaki A, Pollom EL, Steinberg ML, Kishan AU. PMID: 34866018.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncol Pract. 2022 04; 18(4):e484-e494. D'Ambruoso SF, Glaspy JA, Hurvitz SA, Wenger NS, Pietras C, Ahmed K, Drakaki A, Goldman JW, Anand S, Simon W, Kung J, Coscarelli A, Rosen LS, Peddi PF, Wong DJL, Santos K, Phung P, Karlin D, Walling AM. PMID: 34748398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2022 11; 130(5):592-603. Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. PMID: 34597472; PMCID: PMC10257152.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. Radiat Oncol. 2021 Jun 07; 16(1):99. Yoon SM, Suh R, Abtin F, Moghanaki D, Genshaft S, Kamrava M, Drakaki A, Liu S, Venkat P, Lee A, Chang AJ. PMID: 34098977; PMCID: PMC8186067.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    31. Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. Clin Genitourin Cancer. 2021 10; 19(5):425-433. Pond GR, Agarwal A, Ornstein M, Garcia J, Gupta R, Grivas P, Drakaki A, Lee JL, Kanesvaran R, Lorenzo GD, Verolino P, Barata P, Bilen MA, Hussain SA, Curran C, Sonpavde G. PMID: 34006497.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    32. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408. Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, Kim JS, Ferry D, Drakaki A, Bendell J, Naing A. PMID: 33709428; PMCID: PMC8251721.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    33. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537. Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T, IMvigor010 Study Group. PMID: 33721560; PMCID: PMC8495594.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    34. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int. 2021 08; 128(2):196-205. Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. PMID: 33556233.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    35. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 06; 4(3):464-472. Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. PMID: 33423945; PMCID: PMC8169524.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    36. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma. Clin Genitourin Cancer. 2021 06; 19(3):183-193. Abel M, Burkenroad A, Sun A, Lu E, Stefanoudakis D, Drakaki A. PMID: 33558159.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    37. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE). BMC Urol. 2020 Nov 07; 20(1):181. Necchi A, Nishiyama H, Matsubara N, Lee JL, Petrylak DP, de Wit R, Drakaki A, Liepa AM, Mao H, Bell-McGuinn K, Powles T. PMID: 33160359; PMCID: PMC7648381.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    38. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282. Faiena I, Comin-Anduix B, Berent-Maoz B, Bot A, Zomorodian N, Sachdeva A, Said J, Cheung-Lau G, Pang J, Macabali M, Chodon T, Wang X, Cabrera P, Kaplan-Lefko P, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A. PMID: 32925563.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    39. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. Oncoimmunology. 2020 10 05; 9(1):1824645. Drakaki A, Dhillon PK, Wakelee H, Chui SY, Shim J, Kent M, Degaonkar V, Hoang T, McNally V, Luhn P, Gutzmer R. PMID: 33101774; PMCID: PMC7553559.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    40. "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urol Oncol. 2021 01; 39(1):76.e15-76.e22. Drakaki A, Pantuck A, Mhatre SK, Dhillon PK, Davarpanah N, Degaonkar V, Surinach A, Chamie K, Grivas P. PMID: 32778476.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study. Urol Oncol. 2020 11; 38(11):854.e1-854.e9. Lec PM, Lenis AT, Brisbane W, Sharma V, Golla V, Gollapudi K, Blumberg J, Drakaki A, Bergman J, Chamie K. PMID: 32430252.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. VEGF inhibition in urothelial cancer: the past, present and future. World J Urol. 2021 Mar; 39(3):741-749. Ghafouri S, Burkenroad A, Pantuck M, Almomani B, Stefanoudakis D, Shen J, Drakaki A. PMID: 32361873.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    43. Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol. 2020 07; 204(1):63-70. Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P. PMID: 31971495; PMCID: PMC7289665.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    44. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216. Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. PMID: 31829450; PMCID: PMC7050422.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    45. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2020 01; 21(1):105-120. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T, RANGE study investigators. PMID: 31753727; PMCID: PMC6946880.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    46. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol. 2020 02; 77(2):201-208. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. PMID: 31718822; PMCID: PMC7008470.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    47. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Metastatic Cancer Post Solid Organ Transplantation: A Case Report and Review of the Literature. Transplant Proc. 2019 Nov; 51(9):3053-3058. Wong K, Shen J, D'Ambruoso S, Stefanoudakis D, Drakaki A. PMID: 31627918.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443. O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. PMID: 31581306.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    49. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. PMID: 31563517; PMCID: PMC8436252.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    50. Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors. Urol Oncol. 2020 01; 38(1):1.e17-1.e23. Pooli A, Salmasi A, Johnson DC, Lenis AT, Faiena I, Lebacle C, Golla V, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. PMID: 31537483.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. World J Urol. 2020 Jun; 38(6):1525-1533. Heide J, Ribback S, Klatte T, Shariat S, Burchardt M, Dombrowski F, Belldegrun AS, Drakaki A, Pantuck AJ, Kroeger N. PMID: 31520111.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    52. To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. Cancer. 2019 Oct 15; 125(20):3506-3513. Pantuck M, McDermott D, Drakaki A. PMID: 31318445.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    53. Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:284-300. Grivas P, Drakaki A, Friedlander TW, Sonpavde G. PMID: 31099684.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    54. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. Urol Oncol. 2019 09; 37(9):577.e9-577.e16. Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, Salmasi A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. PMID: 30930099; PMCID: PMC6698401.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    55. Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era. Case Rep Oncol Med. 2019; 2019:8349793. Hui G, Ghafouri SN, Shen J, Liu S, Drakaki A. PMID: 31019822; PMCID: PMC6452553.
      View in: PubMed   Mentions: 7  
    56. Second primary lung cancer in United States Cancer Survivors, 1992-2008. Cancer Causes Control. 2019 May; 30(5):465-475. Donin NM, Kwan L, Lenis AT, Drakaki A, Chamie K. PMID: 30900065.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    57. Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. Eur Urol Oncol. 2020 10; 3(5):695-699. Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP. PMID: 31412004.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    58. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma. Cancer Immunol Immunother. 2019 May; 68(5):743-751. Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A. PMID: 30790015.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. JAMA Oncol. 2019 01 01; 5(1):91-96. Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR. PMID: 30326032; PMCID: PMC6440243.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    60. Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better? Urol Oncol. 2019 01; 37(1):63-70. Pooli A, Salmasi A, Faiena I, Lenis AT, Johnson DC, Lebacle C, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. PMID: 30446452.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    61. Rapidly progressive neurologic decline and morbilliform rash presenting in a patient with lymphoma. Clin Pract. 2018 Oct 26; 8(4):1097. Ehrlich D, Phan J, Hui G, Drakaki A. PMID: 30613373; PMCID: PMC6291742.
      View in: PubMed   Mentions:
    62. Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. World J Urol. 2019 Jun; 37(6):1157-1164. Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. PMID: 30267197; PMCID: PMC6438772.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    63. Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma. Urol Oncol. 2018 12; 36(12):527.e13-527.e19. Salmasi A, Faiena I, Lenis AT, Pooli A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. PMID: 30228094.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    64. Next generation T-cell therapy for genitourinary malignancies, part A: Introduction and current state of the art. Cancer Treat Res Commun. 2018; 17:8-12. Pantuck M, Palaskas N, Drakaki A. PMID: 30173005.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    65. Next generation T-cell therapy for genitourinary malignancies, part B: Overcoming obstacles and future strategies for success. Cancer Treat Res Commun. 2018; 17:1-7. Pantuck M, Palaskas N, Drakaki A. PMID: 30170288.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    66. Not Just Another Infection. Am J Med. 2018 11; 131(11):e463-e464. Zhang B, Master AK, Brown CE, Drakaki A. PMID: 30055122.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    67. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol. 2019 Jan; 37(1):115-123. Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. PMID: 29858701.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    68. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. World J Urol. 2018 Nov; 36(11):1825-1833. Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. PMID: 29752514.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    69. MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. Mol Cancer Ther. 2018 07; 17(7):1430-1440. Koutsioumpa M, Chen HW, O'Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A. PMID: 29703843.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    70. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018 05 15; 124(10):2115-2124. Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. PMID: 29517810; PMCID: PMC6857169.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    71. Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy. Eur Urol. 2018 07; 74(1):119-121. Salmasi A, Faiena I, Drakaki A, Pantuck AJ. PMID: 29433972.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    72. Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. Eur Urol. 2018 06; 73(6):981. Faiena I, Salmasi A, Pantuck AJ, Drakaki A. PMID: 29433974.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018; 12:209-215. Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A. PMID: 29416316; PMCID: PMC5789049.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimals
    74. Trends in urinary diversion after radical cystectomy for urothelial carcinoma. World J Urol. 2018 Mar; 36(3):409-416. Bachour K, Faiena I, Salmasi A, Lenis AT, Johnson DC, Pooli A, Drakaki A, Pantuck AJ, Chamie K. PMID: 29299664.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    75. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol. 2018 02; 36(2):78.e21-78.e28. Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K. PMID: 29128421.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    76. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clin Genitourin Cancer. 2018 04; 16(2):e269-e276. Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A. PMID: 29199023.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    77. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. Urol Oncol. 2018 02; 36(2):79.e19-79.e26. Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K. PMID: 29103965.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    78. Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol. 2018 01; 36(1):9.e1-9.e9. Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K. PMID: 29066013.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    79. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies. BMJ Case Rep. 2017 Oct 04; 2017. Way J, Drakaki A, Drexler A, Freeby M. PMID: 28978581; PMCID: PMC5652350.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    80. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017 Nov 18; 390(10109):2266-2277. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T, RANGE study investigators. PMID: 28916371.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    81. Unique microRNA expression in the colonic mucosa during chronic HIV-1 infection. AIDS. 2017 09 10; 31(14):1925-1934. Fulcher JA, Koukos G, Koutsioumpa M, Elliott J, Drakaki A, Iliopoulos D, Anton PA. PMID: 28692540; PMCID: PMC5578872.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    82. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. J Urol. 2018 01; 199(1):43-52. Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K. PMID: 28479237; PMCID: PMC5720927.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    83. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 01 07; 389(10064):67-76. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF, IMvigor210 Study Group. PMID: 27939400; PMCID: PMC5568632.
      View in: PubMed   Mentions: 858     Fields:    Translation:HumansCTClinical Trials
    84. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther. 2017 02; 16(2):376-387. Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. PMID: 27903751; PMCID: PMC5335870.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    85. Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2017 01; 197(1):14-22. Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K. PMID: 27460757.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    86. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer. 2016 10; 122(19):3075-86. Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, Litwin M, Chamie K. PMID: 27377470; PMCID: PMC6192520.
      View in: PubMed   Mentions: 134     Fields:    Translation:Humans
    87. Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification. Case Rep Oncol. 2016 May-Aug; 9(2):298-304. Shin DS, Sherry T, Kallen ME, Wong S, Drakaki A. PMID: 27403128; PMCID: PMC4924467.
      View in: PubMed   Mentions: 6  
    88. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 09 10; 34(26):3119-25. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. PMID: 27269937; PMCID: PMC5569690.
      View in: PubMed   Mentions: 379     Fields:    Translation:HumansCTClinical Trials
    89. A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma. BMC Cancer. 2016 06 03; 16:353. Palumbo T, Poultsides GA, Kouraklis G, Liakakos T, Drakaki A, Peros G, Hatziapostolou M, Iliopoulos D. PMID: 27259577; PMCID: PMC4893280.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    90. Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway. BMC Cancer. 2015 Jul 24; 15:542. Drakaki A, Hatziapostolou M, Polytarchou C, Vorvis C, Poultsides GA, Souglakos J, Georgoulias V, Iliopoulos D. PMID: 26206264; PMCID: PMC4512159.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    91. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. Expert Opin Biol Ther. 2015; 15(8):1205-20. Wainberg ZA, Drakaki A. PMID: 26066903.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    92. MicroRNA-gene signaling pathways in pancreatic cancer. Biomed J. 2013 Sep-Oct; 36(5):200-8. Drakaki A, Iliopoulos D. PMID: 24225187.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    93. Novel immunotherapies in GU malignancies. Curr Oncol Rep. 2013 Jun; 15(3):224-31. Drakaki A, McDermott DF. PMID: 23519772.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    94. Therapeutically targeting microRNAs in liver cancer. Curr Pharm Des. 2013; 19(7):1180-91. Drakaki A, Hatziapostolou M, Iliopoulos D. PMID: 23092338.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    95. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011 Dec 09; 147(6):1233-47. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Iliopoulos D. PMID: 22153071; PMCID: PMC3251960.
      View in: PubMed   Mentions: 252     Fields:    Translation:HumansAnimalsCells
    96. MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene. 2012 Aug 16; 31(33):3818-25. Lee JJ, Drakaki A, Iliopoulos D, Struhl K. PMID: 22120719; PMCID: PMC3290753.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansAnimalsCells
    97. Hypokalemic periodic paralysis due to Graves Disease. Am J Med. 2009 Dec; 122(12):e5-6. Drakaki A, Habib M, Sweeney AT. PMID: 19958876.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. MicroRNA Gene Networks in Oncogenesis. Curr Genomics. 2009 Mar; 10(1):35-41. Drakaki A, Iliopoulos D. PMID: 19721809; PMCID: PMC2699834.
      View in: PubMed   Mentions: 53  
    99. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol. 2009 Feb; 34(2):391-9. Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A. PMID: 19148473.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Alexandra's Networks
    Concepts (300)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (81)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California